Ecolab Strengthens Asian Bioprocessing Network
Ecolab Life Sciences has inaugurated a new Bioprocessing Applications Lab (BPAL) in Dongtan, Korea, marking its first bioprocessing facility in Asia. The new centre aims to enhance bioprocessing capabilities for biopharmaceutical manufacturers globally. This facility supports a full range of process development activities, from early-stage testing to manufacturing-scale studies, building on Ecolab’s existing bioprocessing applications network in the United States and the United Kingdom.
By offering hands-on collaboration with Ecolab’s bioprocessing experts, the BPAL aids customers in optimizing purification processes and advancing programmes toward commercial readiness. Korea has emerged as a global hub for biopharmaceutical manufacturing, particularly in biosimilars which expand access to advanced therapies worldwide.
In this highly competitive environment, manufacturers require speed and technical rigor, aligning with global standards. Jenny Tan, vice president and general manager of Ecolab Life Sciences APAC and India, stated, “Biopharmaceutical manufacturers across Asia are under increasing pressure to scale with speed while meeting demanding regulatory and performance expectations.”
BPAL Korea is part of Ecolab Life Sciences’ ongoing investment in the life sciences sector and reflects innovations across its bioprocessing portfolio, including affinity resin technologies. By expanding its network of development and applications centers worldwide, Ecolab aims to help customers drive growth and scale advanced therapies efficiently.
Korea’s position as a leader in biopharmaceutical manufacturing is further enhanced by BPAL Korea, which supports scalable, regulatory-ready purification processes. The presence of bioprocessing experts locally in Korea allows manufacturers to progress development more efficiently, avoiding overseas material transfers while maintaining consistency and cost efficiencies across global operations.
Ecolab’s commitment to the life sciences industry is evident through its continued innovation and investment, ensuring that customers have access to cutting-edge bioprocessing solutions. By leveraging its global network, Ecolab is poised to support the growth of advanced therapies worldwide.
To learn more about Ecolab Life Sciences’ bioprocess development capabilities and how BPAL Korea supports scalable, regulatory-ready purification processes, visit Ecolab’s Purolite™ Resins website.
